Liane Rae Teplitsky Purchases 1,036 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky purchased 1,036 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the purchase, the chief operating officer owned 1,036 shares in the company, valued at $49,966.28. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Liane Rae Teplitsky also recently made the following trade(s):

• On Friday, August 28th, Liane Rae Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The stock was acquired at an average cost of $48.35 per share, with a total value of $49,993.90.

Pulse Biosciences Price Performance

Shares of PLSE stock traded down $0.99 on Friday, hitting $47.57. The company’s stock had a trading volume of 262,703 shares, compared to its average volume of 406,808. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of -40.31 and a beta of 1.61. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $50.90. The firm’s fifty day moving average price is $35.38 and its 200-day moving average price is $27.00.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Analysts predict that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Analyst Ratings Changes

PLSE has been the subject of several recent analyst reports. Wall Street Zen downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Needham & Company LLC started coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price for the company. Canaccord Genuity Group boosted their target price on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Pulse Biosciences during the 1st quarter worth $323,000. Creative Planning boosted its holdings in Pulse Biosciences by 26.3% during the second quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after acquiring an additional 3,951 shares during the period. Legal & General Group Plc grew its position in shares of Pulse Biosciences by 57.7% in the second quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after purchasing an additional 8,197 shares during the last quarter. Norges Bank acquired a new stake in shares of Pulse Biosciences in the second quarter valued at about $302,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Pulse Biosciences in the second quarter worth about $158,000. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.